Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era

With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confide...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Autores principales: Tao, Li, Clarke, Christina A., Rosenberg, Aaron S., Advani, Ranjana H., Jonas, Brian A., Flowers, Christopher R., Keegan, Theresa H.M.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5487277/
https://ncbi.nlm.nih.gov/pubmed/28542862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14638
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares